Online citations, reference lists, and bibliographies.
← Back to Search

Pancreatic Neuroendocrine Tumors

Joshua S. Hill, J. McPhee, T. McDade, Zheng Zhou, M. Sullivan, G. Whalen, J. Tseng
Published 2009 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Although surgical resection is generally recommended for patients with localized pancreatic neuroendocrine tumors (PNETs), the impact of resection on overall survival is unknown. The authors investigated the survival advantage of pancreatic resection using a national database.
This paper references
10.1007/978-1-4612-4380-9_25
Nonparametric Estimation from Incomplete Observations
E. Kaplan (1958)
Clinical aspects of glucagon-producing islet cell tumors.
R. Prinz (1981)
10.1159/000201197
Revised classification of neuroendocrine tumors of the lung, pancreas and gut.
C. Capella (1994)
10.1097/00000658-199409000-00008
Surgery in Zollinger‐Ellison Syndrome Alters the Natural History of Gastrinoma
D. Fraker (1994)
10.1016/S0002-9610(99)80107-X
Hepatic resection for metastatic neuroendocrine carcinomas.
F. Que (1995)
10.1056/nejm199912303412714
Surgery to cure the Zollinger-Ellison syndrome.
B. Hirschowitz (1999)
10.1016/S1072-7515(00)00222-2
Hepatic neuroendocrine metastases: does intervention alter outcomes?
R. Chamberlain (2000)
Highly aggressive policy of hepatic resections for neuroendocrine liver metastases.
G. Grazi (2000)
Histologic Typing of Endocrine Tumors. World Health Organization International Histology Classification of Tumours
E Solcia (2000)
10.1067/MSY.2001.118367
Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients.
C. Solórzano (2001)
10.1007/s00268-001-0016-5
Treatment of Hepatic Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Role of Liver Transplantation
B. Ringe (2001)
10.1007/978-1-4757-3656-4
AJCC Cancer Staging Manual
M. B. Amin (2002)
10.1002/cncr.11105
A 5‐decade analysis of 13,715 carcinoid tumors
I. Modlin (2003)
10.1016/S1055-3207(02)00076-5
Hepatic surgery for metastases from neuroendocrine tumors.
J. Sarmiento (2003)
10.1016/J.SURG.2003.07.025
Aggressive surgery for metastatic liver neuroendocrine tumors.
J. Norton (2003)
10.1001/ARCHSURG.138.8.859
Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
J. Norton (2003)
10.1016/S1072-7515(03)00230-8
Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.
J. Sarmiento (2003)
10.1007/BF00471177
Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material
L. Griruelius (2004)
10.1007/BF00199342
Revised classification of neuroendocrine tumours of the lung, pancreas and gut
C. Capella (2004)
10.1196/annals.1294.002
The Gastroenteropancreatic Neuroendocrine Cell System and Its Tumors: The WHO Classification
G. Klöppel (2004)
10.1016/J.BPG.2005.04.003
Surgical treatment of neuroendocrine metastases
J. Norton (2005)
Endocrine tumours of the gastrointestinal tract. Surgical treatment of neuroendocrine metastases.
J. Norton (2005)
10.1097/01.sla.0000161981.58631.ab
Neuroendocrine Hepatic Metastases: Does Aggressive Management Improve Survival?
J. Touzios (2005)
10.1001/ARCHSURG.141.8.765
Resection of pancreatic neuroendocrine tumors: results of 70 cases.
K. Kazanjian (2006)
10.1016/B978-1-4160-3256-4.50069-7
Endocrine Tumors of the Pancreas: Clinical Picture, Diagnosis, and Therapy
K. Weber (2007)
10.1097/01.sla.0000232556.24258.68
Aggressive Surgery Improves Long-term Survival in Neuroendocrine Pancreatic Tumors: An Institutional Experience
P. Schurr (2007)
10.1007/s11605-007-0263-3
Clinicopathologic Features and Treatment Trends of Pancreatic Neuroendocrine Tumors: Analysis of 9,821 Patients
K. Bilimoria (2007)
10.1016/S1091-255X(98)80039-5
Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients
G. Phan (2007)
10.1097/CCO.0B013E328011A236
Functioning and nonfunctioning neuroendocrine tumors of the pancreas.
E. Dixon (2007)
10.1016/J.JAMCOLLSURG.2007.05.009
Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors.
K. Bilimoria (2007)
10.1016/j.gassur.2006.08.010
Pancreatic cancer in the general population: Improvements in survival over the last decade
T. Riall (2007)
10.1097/SLA.0b013e3180691579
National Failure to Operate on Early Stage Pancreatic Cancer
K. Bilimoria (2007)
10.1001/ARCHSURG.142.4.347
Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005.
P. A. Vagefi (2007)
10.1245/s10434-007-9566-6
Population-Based Study of Islet Cell Carcinoma
J. Yao (2007)
Hepatic metastases from primary neuroendocrine tumors. In: Blumgart LH, ed. Surgery of the Liver, Biliary Tract, and Pancreas
DM Nagorney (2007)
Hepatic metastases from primary neuroendocrine tumors
DM Nagorney



This paper is referenced by
10.1016/j.ejmp.2020.06.025
Robustness of CT radiomic features against image discretization and interpolation in characterizing pancreatic neuroendocrine neoplasms.
Sara Loi (2020)
10.1371/journal.pone.0235706
Placenta-specific 8 limits IFNγ production by CD4 T cells in vitro and promotes establishment of influenza-specific CD8 T cells in vivo
Chris Slade (2020)
10.1016/j.jchirv.2020.04.015
Chirurgie endocrinienne au cours et au décours de l’épidémie de COVID-19 : recommandations de l’AFCE☆
G. Baud (2020)
10.1016/j.soc.2019.11.008
Surgical Management of Pancreatic Neuroendocrine Tumors.
Tanaz Vaghaiwalla (2020)
10.1016/j.jviscsurg.2020.04.018
Endocrine surgery during and after the COVID-19 epidemic: Expert guidelines from AFCE
G. Baud (2020)
10.1016/j.jchirv.2020.04.015
[Endocrine surgery during and after the COVID-19 epidemic: guidelines from AFCE].
G. Baud (2020)
10.1016/j.soc.2019.11.002
Evolution of Neuroendocrine Tumor Therapy.
T. O'dorisio (2020)
10.1097/MPA.0000000000001535
Aberration of ARID1A Is Associated With the Tumorigenesis and Prognosis of Sporadic Nonfunctional Pancreatic Neuroendocrine Tumors
X. Han (2020)
10.1097/MPA.0000000000001500
Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
M. Squires (2020)
10.1177/0003134820951493
Synchronous Hemihepatectomy With Pancreatectomy Through Application of Associated Liver Partition and Portal Vein Ligation for a Metastatic Gastrinoma.
Brent D Nosé (2020)
10.1007/s00423-020-01868-1
Long-term outcome of surgical resection in patients with gastroenteropancreatic neuroendocrine neoplasia: results from a German nation-wide multi-centric registry
Nehara Begum (2020)
10.1016/j.clinre.2020.04.003
Surgical resection of primary tumor is associated with prolonged survival in low-grade pancreatic neuroendocrine tumors.
Y. Sun (2020)
10.1177/0003134820919730
Predicting Aggressive Behavior in Nonfunctional Pancreatic Neuroendocrine Tumors With Emphasis on Tumor Size Significance and Survival Trends: A Population-Based Analysis of 1787 Patients
A. H. Fathi (2020)
10.1016/j.rcl.2020.07.008
Multimodality Imaging of Neuroendocrine Tumors.
S. Galgano (2020)
10.1016/j.pan.2019.01.007
Can we predict recurrence in WHO G1-G2 pancreatic neuroendocrine neoplasms? Results from a multi-institutional Spanish study.
F. Ausania (2019)
10.1016/J.ANDO.2019.04.009
Gastroenteropancreatic neuroendocrine tumors: Role of surgery.
A. Sauvanet (2019)
10.3348/kjr.2018.0040
What Is New in the 2017 World Health Organization Classification and 8th American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Neoplasms?
J. Choe (2019)
10.4103/eus.eus_28_19
EUS-guided radiofrequency ablation as an alternative to surgery for pancreatic neuroendocrine neoplasms: Who should we treat?
A. Larghi (2019)
10.1245/s10434-019-07252-8
Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately
T. Yoshida (2019)
10.1016/j.media.2019.01.002
Ultrasound guidance in minimally invasive robotic procedures☆
M. Antico (2019)
10.1016/j.critrevonc.2019.102835
Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification.
Hirotaka Ishida (2019)
10.1097/MEG.0000000000001350
Competing risks and cause-specific mortality in patients with pancreatic neuroendocrine tumors
Zhuyin Li (2019)
10.1007/s12022-019-9570-y
MiRNA-3653 Is a Potential Tissue Biomarker for Increased Metastatic Risk in Pancreatic Neuroendocrine Tumours
Preetjote Gill (2019)
10.12998/wjcc.v7.i13.1611
Leveraging machine learning techniques for predicting pancreatic neuroendocrine tumor grades using biochemical and tumor markers
R. Zhou (2019)
10.1007/s11605-019-04113-3
Natural History and Treatment Trends in Pancreatic Cancer Subtypes
C. Pokrzywa (2019)
10.7150/jca.27779
Impact of tumour size on metastasis and survival in patients with pancreatic neuroendocrine tumours (PNETs): A population based study
Yang-yang Liu (2019)
10.1055/S-0038-1675758
Surgery for Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases
Mark S. Etherington (2019)
10.1007/s00423-019-01786-x
Short-term and long-term outcomes after robot-assisted versus laparoscopic distal pancreatectomy for pancreatic neuroendocrine tumors (pNETs): a multicenter comparative study
S. Alfieri (2019)
10.1186/s12885-019-5457-z
Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection
Y. Lv (2019)
10.5348/100084z04mv2019cs
Bleeding and malignant pancreatic neuroendocrine neoplasms: A Malaysian case series
M. Viknesh (2019)
10.1097/SLA.0000000000003461
A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients.
M. Zaidi (2019)
10.5946/ce.2019.068
The Role of Endoscopic Ultrasound-Guided Ki67 in the Management of Non-Functioning Pancreatic Neuroendocrine Tumors
Yong-Chao Cui (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar